02:22, Beijing time, July 2, 2019, Immuron Ltd (IMRN.us) shares changed, the share price plummeted 7.21%. As of press time, the stock was trading at US $2.96 per share, with a turnover of 14622 shares, a turnover rate of 0.36% and an amplitude of 10.50%.

The latest 2018-12-31 data show that the stock achieved operating income of $708526.00, net profit of-$1.15 million, earnings per share of-$0.34, gross profit of $538951.22, and price-to-earnings ratio of-5.22 times.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

The biotech industry in which Immuron Ltd shares are located rose 0.23% as a whole. Among its related stocks, Collplant Biotechnologies Ltd, Ovid Therapeutics Inc and Morphic Holding Inc rose a lot.Satore Medical, Contravir Pharmaceuticals Inc and Sellas Life Sciences Group Inc are more active, with turnover rates of 29.51%, 16.59% and 14.29%, respectively. The related stocks with larger amplitudes are Setoria Medical, Xenetic Biosciences Inc and Morphic Holding Inc, with amplitudes of 32.89%, 30.65% and 27.19%, respectively.

About Immuron Ltd: Immuron is a biopharmaceutical company that develops polyclonal antibodies for the treatment and prevention of diseases. Its products include Travelan, IMM-124E for the treatment of NASH, and IMM-529 for Clostridium labile infection.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )